First Experience with the Prismaflex Hf 20 Set in Four Infants

Abstract

Purpose

Renal replacement therapy (RRT) in infants is challenging due to a lack of widely available technology that is specific to this patient population. We present our initial experience with the newly developed Prismaflex HF2O® disposable set used on the Prismaflex® device in infants with renal failure.

Patients

Four infants, age 5 to 24 months, were enrolled. Overall 120 treatment sessions were performed over 300 patient-days. Treatment monitoring included patient weight change and fluid balance, treatment efficacy, number of interventions, and alarms.

Results

Desired fluid balance according to the prescribed weight loss was achieved in all patients (R²=0.86, p<0.0001). Treatment efficacy was monitored by blood urea nitrogen (BUN) and serum creatinine values at the start of RRT (59±17 mg/dL and 5.1±1.1 mg/dL) and their decrease after 4 hours of RRT (23±7 mg/dL and 2.2±0.6 mg/dL). Measured urea and creatinine clearances for the HF20 filter were 23±7 ml/min and 19±4 ml/min, respectively. No complications occurred.

Conclusion

This is the first report on the use of the Prismaflex HF20 set in infants. No adverse events were observed, treatments were well tolerated in all patients, and flow rate adaptability to infants’ needs was good.